Windward Bio raises €180.0M Series A round

The funding will be used to advance WIN378, a long-acting monoclonal antibody targeting TSLP, for severe asthma and COPD into Phase 2 clinical trials, and to support the advancement of two undisclosed programs through Investigational New Drug (IND)-enabling studies, and build a discovery pipeline of long-acting bispecifics for immunology indications.

Source: https://www.globenewswire.com/news-release/2025/01/10/2927218/0/en/Windward-Bio-Launches-With-200-Million-Series-A-Financing-to-Develop-Phase-2-Ready-Long-Acting-Anti-TSLP-Antibody-With-Best-in-Class-Potential-in-Asthma-and-COPD.html